Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose Escalation and Expansion Study of ABL503, a Bispecific Antibody of 4-1BB and PD-L1, as a Single Agent in Subjects With Any Progressive Locally Advanced (Unresectable) or Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1 Dose Escalation and Expansion Study of ABL503, a Bispecific Antibody of 4-1BB and PD-L1, as a Single Agent in Subjects With Any Progressive Locally Advanced (Unresectable) or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ragistomig (Primary)
  • Indications Gastric cancer; Head and neck cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors ABL Bio

    • Most Recent Events

    • 04 Jun 2024 Results assessing safety and efficacy of ragistomig in patients with advanced solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 30 May 2024 According to a Sarah Cannon Research Institute media release, data from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from Friday, May 31-Tuesday, June 4 in Chicago, Ill.
    • 23 May 2024 According to I-MAB Biopharma media release, The Company announced that Gerald Falchook, MD, and the team at IMabs partner for ragistomig , ABL Bio, will present a poster related to Phase 1 data for ragistomig at the 2024 American Society for Clinical Oncology Annual Meeting taking place from May 31st to June 4th at the McCormick Place Convention Center in Chicago, IL.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top